君圣泰医药-B发布中期业绩 股东应占亏损1.2亿元 同比收窄42.96%

Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) reported a significant decline in other income and a narrowed loss for the six months ending June 30, 2025, indicating challenges in revenue generation but improved loss management [1] Financial Performance - Other income amounted to 10.542 million yuan, representing a year-on-year decrease of 69.96% [1] - Shareholders' loss was 120 million yuan, which is a year-on-year reduction of 42.96% [1] - Basic loss per share was 0.27 yuan [1] Revenue Drivers - The decrease in other income was primarily attributed to a reduction in government subsidies by approximately 19.1 million yuan [1]